Meeting
2020 ASCO Virtual Scientific Program
A phase III randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± linrodostat mesylate, followed by adjuvant postsurgical NIVO ± linrodostat, in cisplatin-eligible muscle invasive bladder cancer (MIBC).
Authors
Guru Sonpavde
Department of Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA
Guru Sonpavde , Andrea Necchi , Shilpa Gupta , Gary D. Steinberg , Juergen Gschwend , Michiel Simon Van Der Heijden , Audrey Richiero , Alexandre Lambert , Bradley Raybold , Srikanth Gajavelli , Dimitrios Zardavas , Matt D. Galsky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT03661320
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS5091)
DOI
10.1200/JCO.2020.38.15_suppl.TPS5091
Abstract #
TPS5091
Poster Bd #
160
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase 3 randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± BMS-986205 in cisplatin-eligible muscle invasive bladder cancer (MIBC).
First Author: Guru Sonpavde
Poster
2020 Genitourinary Cancers Symposium
Phase III study of perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) versus placebo plus neoadjuvant chemo in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-866.
First Author: Arlene O. Siefker-Radtke
Poster
2021 ASCO Annual Meeting
KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).
First Author: Christopher J. Hoimes
Poster
2019 ASCO Annual Meeting
A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA).
First Author: Thomas Powles